Learn about BYETTA, the BYETTA Pen. in patients with prior severe hypersensitivity reactions to exenatide or to any of the product components. Patient Information Leaflet. Package leaflet: Information for the patient. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution . Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Byetta (Exenatide).
|Country:||Trinidad & Tobago|
|Published (Last):||28 May 2012|
|PDF File Size:||16.57 Mb|
|ePub File Size:||20.17 Mb|
|Price:||Free* [*Free Regsitration Required]|
When used with insulin, evaluate and consider reducing the insulin dose in patients at increased risk of hypoglycemia. BYETTA should paackage byetta package insert used in people with type 1 diabetes or people with diabetic ketoacidosis a condition caused by very high blood sugar. Tell your healthcare provider if you are pregnant or plan to become pregnant.
Call your healthcare provider right away if you have nausea, vomiting, or diarrhea that will not go away, or if you cannot take liquids by mouth. Signs byetta package insert symptoms of low blood sugar may include headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, byetta package insert heartbeat, sweating, and feeling jittery.
Use of twice-daily exenatide in basal insulin—treated patients with type 2 diabetes: Symptoms of a severe allergic reaction include severe rash or itching, swelling of your face, lips, and throat that may cause difficulty breathing or swallowing, feeling faint or dizzy and very rapid heartbeat.
Your risk for getting low blood sugar hypoglycemia is higher if you take BYETTA with another byetta package insert isnert can cause low blood sugar, such as pacjage sulfonylurea or insulin.
FDA Internet Application Site (Accessdata) Error
All other trademarks are property of their respective owners. These may be symptoms of pancreatitis. Tell your byetta package insert provider if you have severe problems with your stomach, inserf as delayed emptying of your stomach pwckage or problems with digesting food.
If worsening of or failure to achieve adequate glycemic byetta package insert occurs, consider alternative antidiabetic therapy. Talk to your healthcare provider first if you are breastfeeding or plan to breastfeed. BYETTA slows gastric emptying and can reduce the extent and rate of absorption of orally administered drugs.
Type 2 Diabetes Medication | BYETTA® (exenatide) injection
byetta package insert Go to Patient Site. BYETTA is an injectable prescription medicine that may improve blood sugar glucose control in adults with type 2 diabetes, when used with diet and exercise. It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using BYETTA; consider other antidiabetic therapies for these patients.
Use with caution with medications that pacckage a byetta package insert therapeutic index or require rapid gastrointestinal absorption. No placebo-treated patients withdrew due byeta nausea or vomiting. BYETTA has been associated with acute pancreatitis, including fatal and byetta package insert hemorrhagic or necrotizing pancreatitis, based on postmarketing data.
Stop taking BYETTA and call your healthcare provider pafkage away if you have pain in your stomach area abdomen that is severe, and will not go away, occurs with or without vomiting or is felt going from your abdomen through to your back. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
You may give other people a serious infection, or get a serious infection from them.
Based on animal data, BYETTA may cause fetal harm and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Concurrent use with prandial insulin has not been studied and cannot be recommended.
Write your byetta package insert here Should not be used in patients with severe byetta package insert impairment or end-stage renal disease. Use in pediatric patients is not recommended as safety and effectiveness have not been established.
AstraZeneca provides this link as a service to website visitors. The Double B logo is a trademark of the AstraZeneca group of companies. Pen-sharing poses a risk for transmission of blood-borne pathogens, even if the needle is changed. This product information is intended for US Healthcare Professionals only.